专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11382909B2 Ophthalmic composition 有权
公开(公告)号：US11382909B2
公开(公告)日：2022-07-12
申请号：US16677538
申请日：2019-11-07
申请人： SYDNEXIS, INC.
发明人： Gregory I. Ostrow , Kenneth J. Widder , David S. Baker , Harun Takruri
IPC分类号： A61K31/46 , A61K9/00 , A61K47/02
摘要： Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

2. 发明授权

US09770447B2 Ophthalmic composition 有权
公开(公告)号：US09770447B2
公开(公告)日：2017-09-26
申请号：US15208537
申请日：2016-07-12
申请人： Sydnexis, Inc.
发明人： Gregory I. Ostrow , Kenneth J. Widder , David S. Baker
IPC分类号： A61K31/46 , A61K9/00 , A61K47/02
CPC分类号： A61K31/46 , A61K9/0048 , A61K47/02
摘要： Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

3. 发明授权

US11052094B2 D2O stabilized pharmaceutical formulations 有权
公开(公告)号：US11052094B2
公开(公告)日：2021-07-06
申请号：US15578202
申请日：2016-05-27
申请人： SYDNEXIS, INC.
发明人： Gregory I. Ostrow , Kenneth J. Widder , David S. Baker
IPC分类号： A61K31/5575 , A61K47/02 , A61K9/00 , A61K9/08 , A61K9/06 , A61P27/02 , A61K31/18 , A61K31/216 , A61K31/565 , A61K31/57 , A61K47/34 , A61K47/38
摘要： Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

4. 发明申请

US20160009705A1 OPHTHALMIC COMPOSITION 审中-公开
标题翻译：眼科组合物
公开(公告)号：US20160009705A1
公开(公告)日：2016-01-14
申请号：US14859042
申请日：2015-09-18
申请人： Sydnexis, Inc.
发明人： Gregory I. Ostrow , Kenneth J. Widder , David S. Baker
IPC分类号： C07D451/10 , A61K9/00 , A61K31/46
CPC分类号： C07D451/10 , A61K9/0048 , A61K9/06 , A61K9/08 , A61K31/46 , A61K47/02 , A61K47/38
摘要： Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Additionally disclosed herein include an ophthalmic composition including a low concentration of a deuterated ophthalmic agent. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
摘要翻译：本文提供的是眼用组合物。在一些实施方案中，眼用组合物包含低浓度的用于治疗眼部疾病或病症的眼用药剂; 和眼科学上可接受的载体，其中眼用剂在整个眼科可接受的载体中分布均匀。本文进一步公开的包括眼用组合物，其包含低浓度的眼用剂和氘代水。本文另外公开的包括含有低浓度氘化眼药的眼用组合物。本文还公开了通过向有需要的个体的眼睛施用有效量的本文所述的眼用组合物来阻止或防止近视发展的方法。

5. 发明申请

US20150366854A1 OPHTHALMIC COMPOSITION 有权
标题翻译：眼科组合物
公开(公告)号：US20150366854A1
公开(公告)日：2015-12-24
申请号：US14726139
申请日：2015-05-29
申请人： Sydnexis, Inc.
发明人： Gregory I. Ostrow , Kenneth J. Widder , David S. Baker
IPC分类号： A61K31/46 , A61K9/00
CPC分类号： A61K31/46 , A61K9/0048 , A61K47/02
摘要： Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
摘要翻译：本文提供的是眼用组合物。在一些实施方案中，眼用组合物包含低浓度的用于治疗眼部疾病或病症的眼用药剂; 和眼科学上可接受的载体，其中眼用剂在整个眼科可接受的载体中分布均匀。本文进一步公开的包括眼用组合物，其包含低浓度的眼用剂和氘代水。本文还公开了通过向有需要的个体的眼睛施用有效量的本文所述的眼用组合物来阻止或防止近视发展的方法。

6. 发明授权

US10953002B2 Ophthalmic composition 有权
公开(公告)号：US10953002B2
公开(公告)日：2021-03-23
申请号：US16785416
申请日：2020-02-07
申请人： SYDNEXIS, INC.
发明人： Gregory I. Ostrow , Kenneth J. Widder , David S. Baker , Harun Takruri
IPC分类号： A61K31/46 , A61K47/02 , A61K9/00
摘要： Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

7. 发明授权

US10940145B2 Ophthalmic composition 有权
公开(公告)号：US10940145B2
公开(公告)日：2021-03-09
申请号：US16785418
申请日：2020-02-07
申请人： SYDNEXIS, INC.
发明人： Gregory I. Ostrow , Kenneth J. Widder , David S. Baker , Harun Takruri
IPC分类号： A61K31/46 , A61K47/02 , A61K9/00
摘要： Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

8. 发明授权

US10888557B2 Ophthalmic composition 有权
公开(公告)号：US10888557B2
公开(公告)日：2021-01-12
申请号：US16785413
申请日：2020-02-07
申请人： SYDNEXIS, INC.
发明人： Gregory I. Ostrow , Kenneth J. Widder , David S. Baker , Harun Takruri
IPC分类号： A61K31/46 , A61K47/02 , A61K9/00
摘要： Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

9. 发明授权

US10076515B2 Ophthalmic Composition 有权
公开(公告)号：US10076515B2
公开(公告)日：2018-09-18
申请号：US15661816
申请日：2017-07-27
申请人： Sydnexis, Inc.
发明人： Gregory I. Ostrow , Kenneth J. Widder , David S. Baker
IPC分类号： A61K31/46 , A61K9/00 , A61K47/02
CPC分类号： A61K31/46 , A61K9/0048 , A61K47/02
摘要： Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

10. 发明授权

US11596625B2 Ophthalmic composition 有权
公开(公告)号：US11596625B2
公开(公告)日：2023-03-07
申请号：US17097930
申请日：2020-11-13
申请人： Sydnexis, Inc.
发明人： Gregory I. Ostrow , Kenneth J. Widder , David S. Baker
IPC分类号： A61K31/46 , A61K9/00 , A61K47/02
摘要： Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式